The rapidly growing portfolio - now comprising 27 kits – includes kits for detecting key biomarkers associated with inflammation, cancer, neurodegeneration, metabolic disorders and angiogenesis. With AlphaLISA assays, it is now possible to culture cells and detect key analytes using an “All-in-One-Well” format. The kits can be run in a range of complex biological fluids without the need for arduous separation and wash steps. The AlphaLISA technology saves time and eliminates labor intensive processes that are difficult to automate and which reduce precision and can disrupt weak biomolecular interactions.
“The new ‘All-in-One-Well’ capability greatly enhances the AlphaLISA product line and is a dramatic step forward in simplifying cell-based assays," said Richard Eglen, Ph.D., president, Bio-discovery, PerkinElmer. "AlphaLISA is a robust technology for improving laboratory workflows, eliminating the need for costly washing apparatus and ELISA techniques, as well as facilitating high throughput automation systems.”
In addition to the inflammation, cancer and metabolic disease assays, the “All-in-One-Well” kits now comprise a panel of assays that enables drug development in several critical disease areas. Furthermore, numerous kits allow researchers to detect host cell contamination in biological preparations for therapeutic applications.
AlphaLISA is a proprietary homogenous bead-based assay that is validated with PerkinElmer’s EnVision® Multiplate Label Readers, a highly flexible modular system that detects several assay formats, including TR-FRET, luminescence and fluorescence.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and their environment. The Company reported revenue of $1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
* For Research Use Only. Not for use in diagnostic procedures.
Contact:
Media: PerkinElmer, Inc. Mario Fante, 781-663-5602 mario.fante@perkinelmer.com
Source: PerkinElmer, Inc.
